squamous NSCLC
Oncology · 2016–2016
2decisions
1medicine
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab Treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) in patients who have progressed on or after prior platinum-based… | Mar 2016 | Recommended with restriction | input received Lung Foundation |
| nivolumab Treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) in patients who have progressed on or after prior platinum-based… | Nov 2016 | Deferred | input received |
Who spoke
Lung Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.